Victrix Computational Chemistry and Medicinal Chemistry Consultancy
Contact us
  • Home
  • Philosophy
  • Services
  • Our Clients
  • Contact
  • About
    • Press Releases
  • Victrix Sounds Off
  • Blog

It's the middle of August. Do you know where next years leads are?

8/14/2013

0 Comments

 
Picture
So gentle reader, the ides of August are upon us.  That means that goals slated for accomplishment this year had better be in sight! If you have a clinical candidate in your goals, you had better have your scale-up worked out and your animals ordered for those remaining pharmacology studies and dose ranging tox and PK. If you have programs finishing up, hopefully the screening campaigns are done, so you can order resupply on the hits and you can validate them before the end of the year and have a chance of getting the work done to start on the hit to lead for next year.  If those hit-to-lead campaigns are supposed to move into lead optimization you had better be seeing your primary assay start to produce results that promise the hope of seeing in vivo activity.  That and the annual ritual of filling out your budget like a kid filling out his Christmas list only to have Santa turn into the Grinch and arbitrarily cut 50% off the top.

Ah the Ides of August!

So I want to offer you some help.  If you are stuck optimizing your leads, Victrix can help with structure based and ligand based methods.  If new chemical matter is what you are looking for, we can pull bioisosteres out that will surprise you. Virtual screening, both structure and ligand based can help bring ideas into play that you haven't thought of.  We can help you mine your HTS data and determine false positives and flag potential false negatives for follow-up.  We can build custom PK and tox models to help you out of your DMPK problems.  

It's so cheap, you can't afford not to. Call us for an evaluation.  We will work with your chemists and biologists to give you access to a state of the art computational chemistry and molecular modeling department that uses the same tools as big pharma and the best computational departments with expertise that is the best in class.  I'm sure you are thinking that you can't afford it.  But you can.  You don't need it all the time.  You only pay for access to the tools and expertise you need, when you need it.  Save you head count for another medicinal chemist who can make compounds or another biologist who can generate precious, precious data.  Let us be your computational group.  The only thing you might miss is that sinking feeling when this year’s goals slip out of sight, and you weren't really looking forward to that anyway, were you?




If you enjoy my blog, follow VictrixCMC on LinkedIn, Facebook, and Twitter (@VictrixCMC)

0 Comments

The results are in and they are not good...

8/6/2013

0 Comments

 
Picture
Fierce Biotech reports that only thirteen new entities were approved in the first half of the year, but cautions that it may not be as bad as it looks. If you have been reading my blog, you know I am a bit of a contrarian, and I disagree.  It looks bad. These are the drugs predicted to be blockbusters:

  • Tecfidera (multiple sclerosis): $4.2 billion, Biogen-Idec, dimethyl-fumarate
  • Kadcyla (breast cancer): $2.9 billion, Genentech, antibody conjugate
  • Breo Ellipta (COPD): $1.84 billion, Glaxo+Theravance, Steroid+beta2 agonist
  • Pomalyst (multiple myeloma): $1.28 billion, Celgene, Thalidomide analogue
  • Nesina (diabetes): $1.1 billion, Takeda, DPP4 inhibitor
I'm concerned that there isn't a lot of innovation there.  Breo Elipta is great for Theravance, but it shows that Glaxo has to look elsewhere for innovation.  I've commented before on the inherent problems with DPP4 and the incretin pathway.  Pomalyst is yet another Thalidomide analogue.  This time, at least, it is approved for a solid tumor indication.  Kadcyla is a biologic, and not to denigrate biologics, I'm an orally bioavailable, small molecule guy. I don't get the fumaric acid dimethyl ester.  It's been used since the 50's, is a biocide, and I wonder how it's going to generate $4.2 billion.  

This trend concerns me.  Which brings me to you dear reader.  It's August.  Do your goals include any IND's or clinical candidate nominations for this year?  If so you better have a good scale up route in place to your shot on goal, because it's now officially too late to pull one out of the hat at the last minute.  Also Do you know where your lead series are for next year?  It's time to get cracking.  You need your new chemical mater in place for next year, like last week, dude! Victrix can help.  We are experts at data mining, virtual screening and hit to lead strategies.  Contact us and lets talk about your needs.  It's free.  We will even visit your site and give you an analysis of your needs for free.  Mention this blog for 2 free hours of consulting on top of our free discovery. I'm worried about you and I don't even know you. I want you to meet your goals this year and be in position to get a head start on next years' goals.  You have

If you enjoy my blog, follow VictrixCMC on LinkedIn, Facebook, and Twitter (@VictrixCMC)

0 Comments

Manage your Data in a Secure System or Loose it.

8/2/2013

0 Comments

 
Picture
Full disclosure:  I work with Collaborative Drug Discovery.  I use and love their product.  You may, therefore, take this post with a grain of salt. Nonetheless, I advise you to give the system a solid look.  It is cost effective and easy to use.  If you and your users are familiar with recent generation web apps, you will have an intuitive understanding of the interface.  

Now with that out of the way, What the heck am I talking about? Here is an article on the CDD web site about what is in it for you.  Read it.  Then come back. 

Ok, that was pretty interesting, right?  You see even small startups and academics produce data.  My guess is that if you haven't given this any thought, you are using excel spreadsheets to manage your data.  This is an invitation to disaster.  Registering compounds, tracking their physical properties and biological assay data is something you should be able to do.  You should be able to control access to the data in a straightforward manner. You shouldn't have to pay to maintain an IT infrastructure you don't need.  CDD's cloud based solution addresses all these issues.  Do yourself a favor, and get it today!

If you enjoy my blog, follow VictrixCMC on LinkedIn, Facebook, and Twitter (@VictrixCMC)

0 Comments

On Caffeine, Other Stimulants, both Prescription and Non, and the Neurochemistry of the Above: Or why I side with Voltaire on Coffee and Eschew the use of other Stimulants

8/1/2013

0 Comments

 
Picture
After I posted on, what was in my opinion, a poor use of Nuvigil, several people referred to caffeine as being peddled as a wakefulness enhancer and stimulant for centuries.  True, but caffeine is different neurobiologically than amphetamine like stimulants. 
Amphetamine modulates neurotransmitters in the brain, with the majority of amphetamine effects being exerted on the monoamine neurotransmitters dopamine, serotonin, and norepinephrine. Amphetamine most likely has a much broader effect on the brain and central nervous system dopamine, serotonin, and norepinephrine are just  the most noticeable ones. Amphetamine activity throughout the brain appears to be site-specific. Certain receptors that respond to amphetamine in some regions of the brain tend not to do so in other regions, such as memory formation in the hippocampus. Amphetamine's influence on  neurotransmitter activity specifically in regions implicated in reward explains the behavioral implications of the drug, mainly the  euphoria characteristic of use.

Caffeine is the most widely used psychoactive drug in the world.  I enjoy it in the form of a nice cup of dark roasted coffee of Indonesian or Ethiopian origin.  It is one of those GRAS compounds (generally recognized as safe) that has some pleiotropic effects.

Thus spake Wikipedia: "Adenosine acts as an inhibitor neurotransmitter that suppresses activity in the central nervous system. Consumption of caffeine antagonizes adenosine and increases activity in neurotransmission including acetylcholine, epinephrine, dopamine, serotonin, glutamate, norepinephrine,cortisol, and in higher doses, endorphins which explains the analgesic effect to some users. At very high doses (exceeding 500 milligrams) caffeine inhibits GABA neurotransmission. This evidence explains why caffeine causes anxiety, insomnia, rapid heart and respiration rate."

So instead of bathing my brain in a bath of dopamine, I'll stick to my coffee.  It has other health benefits as well.   I leave you with Voltaire's response to a comment that coffee was a slow poison.  "It must be.  I've drunk 40 cups a day for the last 50 years and I'm not dead yet"

If you enjoy my blog, follow VictrixCMC on LinkedIn, Facebook, and Twitter (@VictrixCMC)

0 Comments

    Adam Kallel Ph. D.

    Our CSO sounds off about drug discovery, computational chemistry and history

    Archives

    March 2014
    January 2014
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013

    Categories

    All
    Ageing
    Amphetamine
    Anti-virals
    Biography
    Broken Society
    Caffeine
    Cancer
    Cd26
    Cluster Headache
    Colic
    Collaboration
    Corona Virus
    Danger Danger
    Depression
    Drug Discovery
    Drug Resistence
    Economy Of Scale
    Electron Microscopy
    Emergent Infectious Disease
    Encephalitis Lethargica
    Global Epidemiology
    Goal Setting
    HCoV-EMC
    Hiring
    Incorrect Pathologizing
    Incretin
    Influenza
    Jobs
    Me
    Merck
    Mergers
    Metabolic Disease
    Migraine
    Nerd
    Neurotransmiters
    Open Positions
    Over Prescription
    Overwork
    Pharma
    Pharmaceutical Industry
    Restructuring
    Stimulants
    Telomerase
    Tuberculosis
    Viral Replication
    Virus

    RSS Feed

    comments powered by Disqus
    View my profile on LinkedIn